These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1551 related articles for article (PubMed ID: 18449410)
41. Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings. Hull RD Thromb Haemost; 2008 Mar; 99(3):502-10. PubMed ID: 18327398 [TBL] [Abstract][Full Text] [Related]
42. New antithrombotic drugs: potential for use in oncology. Levine MN J Clin Oncol; 2009 Oct; 27(29):4912-8. PubMed ID: 19738103 [TBL] [Abstract][Full Text] [Related]
43. [Pharmacologic and clinical principles for rational anti-thrombotic preventive treatment with low molecular weight heparin]. Pindur G; Köhler M; Heiden M; Leipnitz C; Rupp KH; Wenzel E Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():1149-55. PubMed ID: 1983502 [TBL] [Abstract][Full Text] [Related]
44. Mechanism of low-molecular-weight heparin reversal by platelet factor 4. Fiore MM; Mackie IM Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682 [TBL] [Abstract][Full Text] [Related]
45. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Kher A; Bauersachs R; Nielsen JD Thromb Haemost; 2007 Apr; 97(4):505-13. PubMed ID: 17393011 [TBL] [Abstract][Full Text] [Related]
50. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism in at-risk pregnant women: a review. Duhl AJ J Reprod Med; 2008 Sep; 53(9):657-66. PubMed ID: 18839817 [TBL] [Abstract][Full Text] [Related]
51. Pharmacological effects and clinical applications of ultra low molecular weight heparins. Liu Z; Ji S; Sheng J; Wang F Drug Discov Ther; 2014 Feb; 8(1):1-10. PubMed ID: 24647152 [TBL] [Abstract][Full Text] [Related]
52. Antithrombotics in thrombosis and cancer. Mousa SA Hamostaseologie; 2005 Nov; 25(4):380-6. PubMed ID: 16395488 [TBL] [Abstract][Full Text] [Related]
53. New anticoagulants for venous thromboembolic disease. Chang P IDrugs; 2004 Jan; 7(1):50-7. PubMed ID: 14730467 [TBL] [Abstract][Full Text] [Related]
54. Low molecular weight heparins in cancer. Management and prevention of venous thromboembolism in patients with malignancies. ten Cate-Hoek AJ; Prins MH Thromb Res; 2008; 122(5):584-98. PubMed ID: 17996281 [TBL] [Abstract][Full Text] [Related]
55. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. Walenga JM; Lyman GH Crit Rev Oncol Hematol; 2013 Oct; 88(1):1-18. PubMed ID: 23849978 [TBL] [Abstract][Full Text] [Related]
56. The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke. Kiphuth IC; Köhrmann M; Huttner HB; Schellinger PD Expert Opin Drug Saf; 2009 Sep; 8(5):585-97. PubMed ID: 19614560 [TBL] [Abstract][Full Text] [Related]
57. Low- and ultra-low-molecular-weight heparins. Kakkar AK Best Pract Res Clin Haematol; 2004 Mar; 17(1):77-87. PubMed ID: 15171959 [TBL] [Abstract][Full Text] [Related]
58. Clinical studies with anticoagulants to improve survival in cancer patients. Gerotziafas GT; Papageorgiou C; Hatmi M; Samama MM; Elalamy I Pathophysiol Haemost Thromb; 2008; 36(3-4):204-11. PubMed ID: 19176993 [TBL] [Abstract][Full Text] [Related]
59. Heparins in the new millennium: will unfractionated heparin survive? Introduction. McClatchey KD; Galvin HM; Galvin RM Semin Thromb Hemost; 2000; 26 Suppl 1():3-4. PubMed ID: 11011801 [No Abstract] [Full Text] [Related]
60. Update in the treatment of venous thromboembolism. Garcia DA; Spyropoulos AC Semin Respir Crit Care Med; 2008 Feb; 29(1):40-6. PubMed ID: 18302085 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]